Abstracts tagged "Biologics"

Abstract Number: 324 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis
Kim Papp¹, Christopher E.M Griffiths², Kenneth B. Gordon³, Mark Lebwohl⁴, Philippe O. Szapary⁵, Yasmine Wasfi⁵, Daphne Chan⁵, Yaung-Kaung Shen⁵, Vincent Ho⁶, Pierre-Dominique Ghislain⁷, Bruce Strober⁸ and Kristian Reich⁹, ¹Probity Research, Waterloo, ON, Canada, ²Dermatology Centre, University of Manchester, Manchester, United Kingdom, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Mount Sinai Medical Center, New York, NY, ⁵Janssen Research & Development, LLC., Spring House, PA, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷7. Cliniques Universitaires Saint-Luc, Université Catholique de Louvain,, Brussels, Belgium, ⁸University of Connecticut, Farmington, CT, ⁹SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany
Background/Purpose: Ustekinumab(UST) is approved for moderate-to-severe psoriasis (PsO), and is currently in Phase 3 development for psoriatic arthritis (PsA). We report the long-term safety experience…
Abstract Number: 2283 • 2013 ACR/ARHP Annual Meeting
The Evolving Use Of Biologic Monotherapy In Rheumatoid Arthritis and Its Impact On Patient Outcomes
Laurent Chanroux, Katrina Johnson and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom
Background/Purpose: The aim of our study is to understand whether the use of biologic monotherapy among rheumatoid arthritis (RA) patients is increasing and whether this…
Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Gabriela Ávila¹, Sara Marsal¹, Arnald Alonso¹, Carolina Diaz², Estefanía Quesada-Masachs², María López-Lasanta¹ and Isabel Acosta³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, ³Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
Abstract Number: 717 • 2013 ACR/ARHP Annual Meeting
Patients With Rheumatoid Arthritis Have Impaired Candida Albicans Specific Th17 Responses But Preserved Oral Candida Albicans Protective Immunity
Shrinivas Bishu¹, E. Wern Su², Erich Wikerson³, Donald M. Jones⁴, Kelly A. Reckley⁵, Sarah L. Gaffen³ and Marc C. Levesque⁶, ¹Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) patients are susceptible to infections, even after controlling for the effects of medications. Recent data suggest an important role for the…
Abstract Number: 292 • 2013 ACR/ARHP Annual Meeting
Body Surface Area-Based Dosing Approach Produced Comparable Golimumab Exposure Across Different Age Ranges After Subcutaneous Administration Of Golimumab In Pediatric Patients With Juvenile Idiopathic Arthritis
Jocelyn H. Leu¹, Alan M. Mendelsohn², Joyce Ford¹, Hugh M. Davis¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To evaluate the pharmacokinetics (PK) of body surface area (BSA)-adjusted dosing of SC golimumab 30 mg/m2 every 4 weeks (q4w) + methotrexate (MTX)…
Abstract Number: 2269 • 2013 ACR/ARHP Annual Meeting
Patient Reported Pain: A Predictor Of Outcomes In Rheumatoid Arthritis From The Consortium Of Rheumatology Researchers Of North America Registry
Dimitrios A. Pappas¹, Chitra K. Karki², Chin Lee³, George W. Reed⁴, Ping He⁵ and Sarah Al Sawah³, ¹Columbia University, New York, NY, ²Corrona, LLC., Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴CORRONA, Inc., Southborough, MA, ⁵UMASS Medical School, Worcester, MA
Background/Purpose: Pain is a hallmark of rheumatoid arthritis (RA). The extent to which patient reported pain in RA is related to patterns of biologic treatment…
Abstract Number: 1483 • 2013 ACR/ARHP Annual Meeting
Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings
Mariely Nieves-Plaza¹, Heather Eng², Ilinca D. Metes³, Ashwini Shewede⁴, Stephen R. Wisniewski², Ani John⁴ and Marc C. Levesque⁵, ¹Clinical And Translational Science Institute, Univeristy of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Genentech Inc., South San Francisco, CA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Approximately 30% of rheumatoid arthritis (RA) patients treated with a biologic, receive the biologic as monotherapy i.e. without concomitant oral disease modifying anti-rheumatic drugs…
Abstract Number: 522 • 2013 ACR/ARHP Annual Meeting
Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study
PM Meiners¹, A Vissink², Fkl Spijkervet³, EA Haacke⁴, WH Abdulahad⁵, E Brouwer⁵, MG Huitema⁵, N Sillevis Smitt-Kamminga⁶, FGM Kroese⁷, S Arends⁵ and H Bootsma⁵, ¹Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁴Pathology, University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Opthalmology, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Traditional DMARDs have limited effects in primary Sjögren's (pSS) patients. B cell depletion therapy with rituximab showed efficacy, but had some side-effects. T and…
Abstract Number: 193 • 2013 ACR/ARHP Annual Meeting
Physician Variability In Rheumatoid Patients Not Receiving Biologics Or Non-Biologic Dmards: Implications For Quality Reporting
Dimitrios A. Pappas¹, Lang Chen², Leslie R. Harrold³, George W. Reed⁴, Joel M. Kremer⁵, Jeffrey D. Greenberg⁶ and Jeffrey R. Curtis⁷, ¹Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC., Southborough, MA, ⁵Center for Rheumatology, Albany Medical College, Albany, NY, ⁶Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁷University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Current quality of care guidelines recommend that all patients with Rheumatoid Arthritis (RA) be treated with biologic and/or non-biologic (nb) DMARDs. However, some RA…
Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting
COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
Abstract Number: 1473 • 2013 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor α Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels To a Greater Extent Than Triple Oral Disease Modifying Anti-Rheumatic Drug Therapy In Early Rheumatoid Arthritis Subjects
Ilinca D. Metes¹, Douglas W. Chew¹, Aarat M. Patel¹, G.K. Balasubramani², S. Louis Bridges Jr.³, Jeffrey R. Curtis⁴, Stephen R. Wisniewski², Larry W. Moreland⁵ and Marc C. Levesque⁶, ¹Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Amyloidosis is often due to an underlying inflammatory disorder, such as rheumatoid arthritis (RA), with organ deposition of serum amyloid A (SAA). Oral disease…
Abstract Number: 502 • 2013 ACR/ARHP Annual Meeting
Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort
Cécile Gaujoux-Viala¹, Laure Gossec², Maxime Dougados³, Francis Guillemin⁴ and Bruno Fautrel⁵, ¹EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Rheumatology, Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ³Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability [1]. The concept of favorable outcome…
Abstract Number: 194 • 2013 ACR/ARHP Annual Meeting
Team Managed Care From a Patient’s Perspective: A Study Of Biological Patients At a Canadian Centre
Dawn Heap¹, Margaret Saldanha¹, Melissa Deamude¹, Cynthia Mech², Helena Ross¹, Kathy Kislinsky¹, Lauri Vanstone³, Arthur N. Lau⁴ and William G. Bensen⁵, ¹Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ²Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr. William Bensen Rheumatology Biologic Clinic, Rheumatology Health Team, Hamilton, ON, Canada, ⁴Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: In Canada, there is a widening care gap in Inflammatory Arthritis due to the increased aging population, higher disease prevalence, dwindling numbers of practicing…
Abstract Number: 2031 • 2013 ACR/ARHP Annual Meeting
GRAID – Interim Analysis Of The Retrospective German Register In Autoimmune Diseases
Thomas Dörner¹, Enno Schmidt², Christoph Fiehn³, Frank Behrens⁴, Rebecca Fischer-Betz⁵, Martin Fleck⁶, Julia Holle⁷, Joerg C. Henes⁸, Annett M. Jacobi⁹, Christian Kneitz¹⁰, Esther Wittenborn¹¹, Fabian Proft¹², Hendrik Schulze-Koops¹³ and Christof Iking-Konert¹⁴, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Department of Dermatology, University of Lübeck, Lübeck, Germany, ³ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ⁴CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ⁵Department of Rheumatology, University of Düsseldorf, Düsseldorf, Germany, ⁶Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, ⁷Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ⁹Rheumatology Internal Medicine D, University Hospital Münster, Münster, Germany, ¹⁰Internal Medicine II, Hospital Südstadt, Rostock, Germany, ¹¹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹²Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ¹³Division of Rheumatology, University of Munich, Munich, Germany, ¹⁴Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: Autoimmune diseases are characterized by high morbidity and lead frequently to physical disability and loss of income. They are the third most important disease…
Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
T.W.J. Huizinga¹, Fiona Brock², Urs Kerkmann³ and Gaia Gallo³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Quanticate, Hitchin, Hertfordshire, United Kingdom, ³Pfizer Europe, Rome, Italy
Background/Purpose: Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.